Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
SUSPENDED
NCT03186456
PHASE1

The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction

Sponsor: Sclnow Biotechnology Co., Ltd.

View on ClinicalTrials.gov

Summary

The purposes of the study is to determine the safety and efficacy of treating acute ischemic stroke patients with human umbilical cord mesenchymal stem cells (hUC-MSC).

Official title: Study the Safety and Efficacy of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Acute Cerebral Infarction

Key Details

Gender

All

Age Range

40 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2026-12-31

Completion Date

2027-12-31

Last Updated

2026-04-23

Healthy Volunteers

No

Interventions

BIOLOGICAL

Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)

Allogeneic umbilical cord mesenchymal stem cells will transfusion into by forearm intravenous transplantation, 0.5 - 1 \*10\^6/kg. once a month, total 3 times.

DRUG

Aspirin Tablet

Drug: Aspirin Tablet, 100 mg/d

Locations (1)

Inner Mongolia International Mongolian Hospital

Hohhot, Inner Mongolia, China